Navigation Links
FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications
Date:3/16/2011

SILVER SPRING, Md., March 16, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration and the European Medicines Agency (EMA) have launched a new pilot program that will allow parallel evaluation of relevant development and manufacturing data components, known as Quality by Design (QbD), of new drug marketing applications that are submitted to both agencies.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The parallel evaluation within this voluntary pilot program means that reviewers from both agencies will separately assess the quality/chemistry, manufacturing and control (CMC) section of the new drug applications (NDAs) submitted to the FDA and marketing authorization applications (MAAs) submitted to the EMA.  However, there will be regular communication and consultation between European regulators and their U.S. colleagues throughout the review process relevant to QbD aspects of the applications.  

QbD in pharmaceuticals involves designing and developing pharmaceutical formulations and manufacturing processes to help ensure product manufacturing quality. Several guidelines have been developed by the International Conference on Harmonisation (ICH) to harmonize and facilitate the implementation of QbD. This pilot program began out of concern that certain ICH guidelines were being interpreted differently in Europe and the United States. Goals of the pilot program include:  

  • Helping to ensuring consistent implementation of ICH guidelines for manufacturing quality in the application evaluation process
  • Increasing awareness of these regulatory concepts by staff that review marketing applications and inspect manufacturing facilities as part of the approval process
  • Defining the reviewer and inspector interaction for QbD applications
  • Creating a further way for EMA and FDA assessors/reviewers to share full knowledge about these applications
  • Developing and harmonizing regulatory decisions to the greatest extent possible.

"As the number of applications that follow the QbD approach steadily increases, collaborative assessments will enhance understanding of QbD concepts. The tools used by FDA and EU reviewers will increase information sharing and reduce redundancy," said Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research. "To fully implement QbD, we need to further harmonize the implementation of the guidelines, work collaboratively, and provide scientific, risk-based regulatory decisions in a timely manner."

"This is another concrete example of the very collaborative working relationship we have with our European regulatory colleagues and how we can leverage the scientific resources we both have for the benefit of our agencies and our citizens," said Murray M. Lumpkin, M.D., Deputy Commissioner of FDA's Office of International Programs.  

This pilot program applies to NDAs and MAAs, some supplements, and CMC meeting requests that include QbD elements submitted to both agencies at about the same time. The pilot will only include chemical entities and not biologically-derived products. Review of QbD applications does not change statutory deadlines. The pilot will end on March 31, 2014.

For more information:

International Conference on Harmonization - Quality Guidance

European Medicines Agency

International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)

Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA




'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
2. Shanghai ChemPartner Announces Being Selected as Antibody Service Partner by Shenogen Pharma Group
3. China Nepstar Chain Drugstore Announces Management Appointments
4. Nephros Announces Split Adjusted Trade Date
5. Harris Corporation and Johns Hopkins Medicine Announce Joint Venture to Develop Innovative Medical Image Management Solutions
6. Bionovo Announces 2010 Highlights and Year-End Financial Results
7. Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
8. The Electro-Nail - Better Design for Faster Healing. ICAP Ocean Tomo Announces Auction of an Advanced Electro-Nail Implant System for Electro-Magnetic Bone Stimulation in Orthopedics
9. Healthier Healing for Hip Resurfacing - ICAP Ocean Tomo Announces Auction of an Advanced Hip Cap for Electromagnetic Tissue Stimulation by Neue Magnetodyn.
10. LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry
11. China Sky One Medical Announces Fourth Quarter and Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology:
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
Breaking Medicine News(10 mins):